MUC1-C activates the TAK1 inflammatory pathway in colon cancer

Oncogene

Volumn 34, Issue 40, 2015, Pages 5187-5197

  Takahashi, H ^a   Jin, C ^b   Rajabi, H ^a   Pitroda, S ^c   Alam, M ^a   Ahmad, R ^a,d   Raina, D ^b   Hasegawa, M ^a   Suzuki, Y ^a   Tagde, A ^a   Bronson, R T ^a   Weichselbaum, R ^c   Kufe, D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Genus Oncology   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; MESSENGER RNA; MUC1 C PROTEIN; MUCIN 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MUC1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; EXPERIMENTAL COLITIS; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN TARGETING; RECURRENCE FREE SURVIVAL; TRANSACTIVATION; ULCERATIVE COLITIS; UPREGULATION; ANIMAL; C57BL MOUSE; CHROMATIN IMMUNOPRECIPITATION; COLON TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCIN-1; NF-KAPPA B; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; SIGNAL TRANSDUCTION;

EID: 84943197710     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.442     Document Type: Article

References (50)

1. Kufe D. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874-885.
2. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004; 23: 77-99.
3. Suzuki H, Shoda J, Kawamoto T, Shinozaki E, Miyahara N, Hotta S et al. Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma. Clin Exp Metastasissis 2004; 21: 321-329.
4. Niv Y. MUC1 and colorectal cancer pathophysiology considerations. World J Gastroenterol 2008; 14: 2139-2141.
5. Lugli A, Zlobec I, Baker K, Minoo P, Tornillo L, Terracciano L et al. Prognostic significance of mucins in colorectal cancer with different DNA mismatchrepair status. J Clin Pathol 2007; 60: 534-539.
6. Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 1994; 106: 353-361.
7. Baldus SE, Monig SP, Hanisch FG, Zirbes TK, Flucke U, Oelert S et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology 2002; 40: 440-449.
8. Duncan TJ, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer. World J Surg Oncol 2007; 5: 31.
9. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
10. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks GSK3β-mediated phosphorylation and degradation of β-catenin. Cancer Res 2005; 65: 10413-10422.
11. Rajabi H, Ahmad R, Jin C, Kosugi M, Alam M, Joshi M et al. MUC1-C oncoprotein induces TCF7L2 activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem 2012; 287: 10703-10713.
12. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S, Kufe D. MUC1-C oncoprotein functions as a direct activator of the NF-κB p65 transcription factor. Cancer Res 2009; 69: 7013-7021.
13. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003; 22: 6107-6110.
14. Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-apoptotic PI3K/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 2004; 279: 20607-20612.
15. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S et al. MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signaling. Nat Cell Biol 2007; 9: 1419-1427.
16. Rajabi H, Alam M, Takahashi H, Kharbanda A, Guha M, Ahmad R et al. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelialmesenchymal transition. Oncogene 2013; 33: 1680-1689.
17. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 2012; 33: 522-530.
18. Ajibade AA, Wang HY, Wang RF. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol 2013; 34: 307-316.
19. Omori E, Matsumoto K, Zhu S, Smart RC, Ninomiya-Tsuji J. Ablation of TAK1 upregulates reactive oxygen species and selectively kills tumor cells. Cancer Res 2010; 70: 8417-8425.
20. Ray DM, Myers PH, Painter JT, Hoenerhoff MJ, Olden K, Roberts JD. Inhibition of transforming growth factor-beta-activated kinase-1 blocks cancer cell adhesion, invasion, and metastasis. Br J Cancer 2012; 107: 129-136.
21. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012; 148: 639-650.
22. Mihaly SR, Ninomiya-Tsuji J, Morioka S. TAK1 control of cell death. Cell Death Differ 2014; 21: 1667-1676.
23. Relic B, Benoit V, Franchimont N, Ribbens C, Kaiser MJ, Gillet P et al. 15-deoxy-delta12,14-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J Biol Chem 2004; 279: 22399-22403.
24. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitindependent kinase of MKK and IKK. Nature 2001; 412: 346-351.
25. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K, Gaynor RB. TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J Mol Biol 2003; 326: 105-115.
26. Yamazaki K, Gohda J, Kanayama A, Miyamoto Y, Sakurai H, Yamamoto M et al. Two mechanistically and temporally distinct NF-kappaB activation pathways in IL-1 signaling. Sci Signal 2009; 2: ra66.
27. Starczynowski DT, Lockwood WW, Delehouzee S, Chari R, Wegrzyn J, Fuller M et al. TRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancer. J Clin Invest 2011; 121: 4095-4105.
28. Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S, Kufe D. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol 2012; 40: 1643-1649.
29. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013; 23: 121-128.
30. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-1816.
31. Campbell BJ, Yu LG, Rhodes JM. Altered glycosylation in inflammatory bowel disease: a possible role in cancer development. Glycoconj J 2001; 18: 851-858.
32. Rhodes JM. Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Lancet 1996; 347: 40-44.
33. Furr AE, Ranganathan S, Finn OJ. Aberrant expression of MUC1 mucin in pediatric inflammatory bowel disease. Pediatr Dev Pathol 2010; 13: 24-31.
34. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 1998; 58: 315-321.
35. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996; 98: 1010-1020.
36. Beatty PL, Plevy SE, Sepulveda AR, Finn OJ. Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol 2007; 179: 735-739.
37. Ahmad R, Rajabi H, Kosugi M, Joshi M, Alam M, Vasir B et al. MUC1-C oncoprotein promotes STAT3 activation in an auto-inductive regulatory loop. Sci Signal 2011; 4: ra9.
38. Khodarev N, Pitroda S, Beckett M, MacDermed D, Huang L, Kufe D et al. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 2009; 69: 2833-2837.
39. Cai PC, Shi L, Liu VW, Tang HW, Liu IJ, Leung TH et al. Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-kappaB signaling. Oncotarget 2014; 5: 7549-7562.
40. Omori E, Inagaki M, Mishina Y, Matsumoto K, Ninomiya-Tsuji J. Epithelial transforming growth factor beta-activated kinase 1 (TAK1) is activated through two independent mechanisms and regulates reactive oxygen species. Proc Natl Acad Sci USA 2012; 109: 3365-3370.
41. Kufe D. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2013; 32: 1073-1081.
42. McAuley JL, Linden SK, Png CW, King RM, Pennington HL, Gendler SJ et al. MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. J Clin Invest 2007; 117: 2313-2324.
43. Hoebler C, Gaudier E, De Coppet P, Rival M, Cherbut C. MUC genes are differently expressed during onset and maintenance of inflammation in dextran sodium sulfate-treated mice. Dig Dis Sci 2006; 51: 381-389.
44. Petersson J, Schreiber O, Hansson GC, Gendler SJ, Velcich A, Lundberg JO et al. Importance and regulation of the colonic mucus barrier in a mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 2011; 300: G327-G333.
45. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296.
46. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-113.
47. Alam M, Ahmad R, Rajabi H, Kharbanda A, Kufe D. MUC1-C oncoprotein activates ERK→C/EBPβ-mediated induction of aldehyde dehydrogenase activity in breast cancer cells. J Biol Chem 2013; 288: 30829-30903.
48. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Therapeut 2011; 10: 806-816.
49. Panchamoorthy G, Rehan H, Kharbanda A, Ahmad R, Kufe D. A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain. Hybridoma 2011; 30: 531-535.
50. Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005; 19: 631-642.